Eli Lilly is expected to report a significant increase in earnings and revenue for the first quarter of 2025.
The ACHIEVE-1 trial results for orforglipron have positively impacted Eli Lilly’s stock, showcasing potential leadership in oral obesity treatments.
The stock shows a bullish trend, trading above key moving averages and indicating a positive outlook for long-term investors.
Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company based in Indianapolis, known for its innovative treatments and therapies. The company is set to release its first-quarter earnings on May 1, 2025. Guggenheim has maintained a “Buy” rating for LLY, with the stock price at $898.95, as highlighted by Benzinga.
Analysts expect Eli Lilly to report earnings of $3.46 per share, a notable increase from $2.58 per share in the same period last year. The anticipated revenue is $12.72 billion, up from $8.77 billion a year earlier. This growth reflects the company’s strong performance and strategic advancements in the pharmaceutical sector.
Eli Lilly’s recent topline Phase 3 results from the ACHIEVE-1 trial of orforglipron have positively impacted its stock, which rose by 1.6% to $898.95. The trial showed promising results for type 2 diabetes patients, positioning orforglipron as a potential leader in oral obesity treatments, comparable to existing therapies like oral and injectable semaglutide.
The stock’s technical indicators show a bullish trend, trading above key moving averages. LLY is above its five-day, 20-day, and 50-day exponential moving averages, as well as its eight-day, 20-day, and 50-day simple moving averages. It also remains above its 200-day SMA of $844.59, a positive sign for long-term investors.
Eli Lilly’s stock has performed well, rising 14.35% over the past year and 14.79% year-to-date. The current stock price of $898.95 reflects a 1.55% increase, with a trading range between $882.12 and $902.50. The company’s market capitalization is approximately $852.19 billion, with a trading volume of 3,154,448 shares on the NYSE.
